How to use Technology Offers
The `Technologies offered´-section displays product and technology opportunities. Text search allows the use of phrases not yet part of the category lists. Key words can be used in combination and help identifying the hits most relevant for you.
A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in `Sector´, "Cancerous, neoplasmatic" in `Disease Category, "Drugs, Small Molecule" in `Technology´ and "Preclinical" in `Development Stage´.
Selection of "Enabling Technology, Platform Technology" in `Sector´ will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.
Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.
Registered users can create non-public notifications profiles which will inform them about new Technology Offered entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.
691 results found
Displaying results 121 to 140 out of 691

- Means and Methods for Treating Peripheral and Cardiovascular Diseases via Modulation of Arteriogenesis offered by Max-Planck-Innovation
Trpv4 is highly suitable for the development of new therapeutic concepts in order to cure peripheral and cardiovascular diseases
- New preclinical stage prostate cancer drug inhibits prostate tumor growth and metastasis in a different mode of action than current anti-cancer drugs
inhibits human prostate cancer cell metastasis as efficiently as combretastatin
- Sanofi Pasteur is seeking opportunities in vaccines, antibodies and supporting technologies for prevention of treatment of infectious diseases
novel antigens, carrier proteins, adjuvants, vaccine vectors, basic immunology, fermentor and bioreactor technology, preservatives and stabilizers, biological markers, epidemiological studies
- Bavarian Nordic is interested in Dendritic, T- and NK-cell activating genes and tumor-associated antigens or other relevant antigens
- New Antimalarials offered by AWSG, Vienna
A new bridged compound shows significant activity against a multiresistant strain of Plasmodium falciparum and against Plasmodium berghei in a mouse model
© 2006-2007
by Herbert-Worch-Foundation